107. Juvenile idiopathic arthritis Clinical trials / Disease details


Clinical trials : 441 Drugs : 282 - (DrugBank : 56) / Drug target genes : 52 - Drug target pathways : 142

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-002788-88-NL
(EUCTR)
23/09/202118/02/2021Apremilast Study in Children with Active Juvenile Psoriatic ArthritisA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD) Juvenile psoriatic arthritis
MedDRA version: 20.0;Level: LLT;Classification code 10079454;Term: Systemic juvenile idiopathic arthritis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Otezla
Product Name: Apremilast 10 mg
Product Code: AMG-407
INN or Proposed INN: Apremilast
Trade Name: Otezla
Product Name: Apremilast 20 mg
Product Code: AMG-407
INN or Proposed INN: Apremilast
Trade Name: Otezla
Product Name: Apremilast 30 mg
Product Code: AMG-407
INN or Proposed INN: Apremilast
Product Name: Apremilast
Product Code: AMG407
INN or Proposed INN: Apremilast
Amgen Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 3France;Belgium;Austria;Netherlands;Italy
2EUCTR2019-002788-88-FR
(EUCTR)
15/04/202118/12/2020Apremilast Study in Children with Active Juvenile Psoriatic ArthritisA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD) Juvenile psoriatic arthritis
MedDRA version: 20.0;Level: LLT;Classification code 10079454;Term: Systemic juvenile idiopathic arthritis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Otezla
Product Name: Apremilast 10 mg
Product Code: AMG-407
INN or Proposed INN: Apremilast
Trade Name: Otezla
Product Name: Apremilast 20 mg
Product Code: AMG-407
INN or Proposed INN: Apremilast
Trade Name: Otezla
Product Name: Apremilast 30 mg
Product Code: AMG-407
INN or Proposed INN: Apremilast
Product Name: Apremilast
Product Code: AMG407
INN or Proposed INN: Apremilast
Amgen Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 3France;Belgium;Austria;Netherlands
3EUCTR2019-002788-88-IT
(EUCTR)
11/03/202120/05/2021Apremilast Study in Children with Active Juvenile Psoriatic ArthritisA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD) - PEAPOD Juvenile psoriatic arthritis
MedDRA version: 20.0;Level: LLT;Classification code 10079454;Term: Systemic juvenile idiopathic arthritis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA 30 MG
Product Name: Apremilast 20 mg
Product Code: [AMG407]
INN or Proposed INN: Apremilast
Trade Name: OTEZLA - 30 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/ALU) - 56 COMPRESSE
Product Name: Apremilast 30 mg
Product Code: [AMG407]
INN or Proposed INN: Apremilast
Trade Name: OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA 30 MG
Product Name: Apremilast 10 mg
Product Code: [AMG407]
INN or Proposed INN: Apremilast
Product Name: Apremilast
Product Code: [AMG407]
INN or Proposed INN: Apremilast
AMGEN INC.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 3France;Spain;Belgium;Austria;Netherlands;Germany;Italy
4EUCTR2019-002788-88-BE
(EUCTR)
15/12/2020Apremilast Study in Children with Active Juvenile Psoriatic ArthritisA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD) Juvenile psoriatic arthritis
MedDRA version: 20.0;Level: LLT;Classification code 10079454;Term: Systemic juvenile idiopathic arthritis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Otezla
Product Name: Apremilast 10 mg
Product Code: AMG-407
INN or Proposed INN: Apremilast
Trade Name: Otezla
Product Name: Apremilast 20 mg
Product Code: AMG-407
INN or Proposed INN: Apremilast
Trade Name: Otezla
Product Name: Apremilast 30 mg
Product Code: AMG-407
INN or Proposed INN: Apremilast
Product Name: Apremilast
Product Code: AMG407
INN or Proposed INN: Apremilast
Amgen Inc.NULLNAFemale: yes
Male: yes
60Phase 3Belgium;Austria;Netherlands
5EUCTR2019-002788-88-AT
(EUCTR)
05/11/2020Apremilast Study in Children with Active Juvenile Psoriatic ArthritisA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD) Juvenile psoriatic arthritis
MedDRA version: 20.0;Level: LLT;Classification code 10079454;Term: Systemic juvenile idiopathic arthritis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Otezla
Product Name: Apremilast 10 mg
Product Code: AMG-407
INN or Proposed INN: Apremilast
Trade Name: Otezla
Product Name: Apremilast 20 mg
Product Code: AMG-407
INN or Proposed INN: Apremilast
Trade Name: Otezla
Product Name: Apremilast 30 mg
Product Code: AMG-407
INN or Proposed INN: Apremilast
Product Name: Apremilast
Product Code: AMG407
INN or Proposed INN: Apremilast
Amgen Inc.NULLNAFemale: yes
Male: yes
60Phase 3France;Belgium;Austria;Netherlands;Italy
6EUCTR2019-002788-88-PL
(EUCTR)
28/01/2022Apremilast Study in Children with Active Juvenile Psoriatic ArthritisA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD) Juvenile psoriatic arthritis
MedDRA version: 20.0;Level: LLT;Classification code 10079454;Term: Systemic juvenile idiopathic arthritis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Otezla
Product Name: Apremilast 10 mg
Product Code: AMG-407
INN or Proposed INN: Apremilast
Trade Name: Otezla
Product Name: Apremilast 20 mg
Product Code: AMG-407
INN or Proposed INN: Apremilast
Trade Name: Otezla
Product Name: Apremilast 30 mg
Product Code: AMG-407
INN or Proposed INN: Apremilast
Product Name: Apremilast
Product Code: AMG407
INN or Proposed INN: Apremilast
Amgen Inc.NULLNAFemale: yes
Male: yes
60Phase 3France;Belgium;Poland;Austria;Netherlands;Italy